Analyst Research

Report Title Price
Provider: S&P Capital IQ Factual Report
$150.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cubist Pharmaceuticals Inc Completes Acquisition Of Optimer Pharmaceuticals


Thursday, 24 Oct 2013 09:45am EDT 

Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc for an aggregate upfront cash consideration of approximately $551 million. Optimer stockholders approved the merger agreement at a special meeting of stockholders held on October 23, 2013. Effective on October 24, 2013, Optimer common stock will cease to be traded on the NASDAQ. Cubist's acquisition of Optimer follows the Company's September 11, 2013 acquisition of Trius Therapeutics. 

Company Quote

70.93
-1.49 -2.06%
24 Oct 2014